Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Approximately 3 million people in the United States are living with inflammatory bowel
disease, which includes Crohn's Disease, with many of those being young children and
adolescents. Physicians need better ways to inform decisions on treatment.
The main reason for this research study is to determine if a computer program that formulates
a dose based on a patient's blood testing results can better achieve the optimal drug level
as compared to standard dosing.